Overweight and obese patients on gastroenterological visit
https://doi.org/10.33667/2078-5631-2022-12-7-11
Abstract
The article presents the results of a cross-sectional study conducted at the St. Petersburg City Hospital No. 26 to identify the most common complaints and diseases of the digestive system in overweight and obese patients at gastroenterological appointments. The work analyzed the outpatient admission cards of 298 patients who visited a gastroenterologist. Body mass index (BMI) more than 25 kg/m2 was determined in 151 (50.67 %) patients. The most common complaints in overweight and obese patients were regurgitation, heartburn, bloating and rumbling in the stomach, diarrhea, morning cough and hoarseness, abdominal pain, feeling of heaviness and fullness after eating, constipation. Gastroesophageal disease was diagnosed in 103 (68.2 %) patients, functional bowel disease with a predominance of diarrhea in 54 (35.76 %) patients, biliary sludge in 54 (35.76 %) patients, non-alcoholic fatty liver disease in 50 (33.11 %), cholelithiasis in 49 (32.45 %), chronic gastritis in 43 (28.47 %), functional constipation in 32 (21.19 %), organic diseases of the colon in 24 (15.89 %), peptic ulcer of the stomach and duodenum in 11 (7.28 %) patients.
About the Authors
S. V. Tikhonov
North-Western State Medical University n.a. I. I. Mechnikov
Russian Federation
Russian Federation
Tikhonov Sergey V., PhD Med, associate professor at Dept of Internal Medicine, Clinical Pharmacology and Nephrology
Saint Petersburg
N. V. Bakulina
North-Western State Medical University n.a. I. I. Mechnikov
Russian Federation
Russian Federation
Bakulina Natalya V., DM Sci (habil.), professor, head of Dept of Internal Medicine, Clinical Pharmacology and Nephrology
Saint Petersburg
V. I. Simanenkov
North-Western State Medical University n.a. I. I. Mechnikov
Russian Federation
Russian Federation
Simanenkov Vladimir I., DM Sci (habil.), professor at Dept of Internal Medicine, Clinical Pharmacology and Nephrology
Saint Petersburg
References
1. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000; 894: i–xii, 1–253.
2. https://www.who.int/ru/news-room/fact-sheets/detail/obesity-and-overweight. Обращение от 12.04.2021.
3. Kontsevaya A. S., Shalnova S. A., Drapkina O. M. ESSE-RF Study: Epidemiology and Public Health Promotion. Cardiovascular therapy and prevention. 2021; 20 (5): 224–232.
4. Zhou Y., Chi J., Lv W., Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19). Diabetes Metab Res Rev. 2021; 37 (2): e3377. DOI: 10.1002/dmrr.3377.
5. Johnson D. A. Gastroenterologic Issues in the Obese Patient, An Issue of Gastroenterology Clinics. 2010. Elsevier Health Sciences. 169 p.
6. Andres A., Michael C. Gastrointestinal Morbidity in Obesity. Ann NY Acad Sci. 2014; 1311: 42–56.
7. Anggiansah R., Sweis R., Anggiansah A. The effects of obesity on oesophageal function, acid exposure and the symptoms of gastroesophageal reflux disease. Alimentary pharmacology & therapeutics. 2013; 37 (5): 555–563.
8. Ryan A., Duong M., Healy L., et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer epidemiology. 2011; 35 (4): 309–19.
9. Ogunwobi O., Beales I. Leptin stimulates the proliferation of human oesophageal adenocarcinoma cells via HB-EGF and Tgf-alpha mediated transactivation of the epidermal growth factor receptor. British journal of biomedical science. 2008; 65 (3): 121–7.
10. Drossman D. A. Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. Gastroenterology. 2016 Feb 19: S 0016–5085 (16) 00223–7. DOI: 10.1053/j.gastro.2016.02.032. Epub ahead of print. PMID: 27144617.
11. Ferlay J., Soerjomataram I., Ervik M., et al. Cancer Incidence and Mortality Worldwide. IARC Cancer Base. GLOBOCAN. 2015; 136 (5): 359–386.
12. Sedjo R. L., Byers T., Levin T. R., et al. Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2007; 16 (3): 526–531.
13. Almendingen K., Hofstad B., Vatn M. H. Does high body fatness increase the risk of presence and growth of colorectal adenomas followed up in situ for 3 years? Am J Gastroenterol. 2001; 96 (7): 2238–2246.
14. Alemán J. O., Eusebi L. H., Ricciardiello L., et al. Mechanisms of obesity induced gastrointestinal neoplasia. Gastroenterology. 2014; 146 (2): 357–373.
15. Dali-Youcef N., Mecili M., Ricci R., et al. Metabolic inflammation: Connecting obesity and insulin resistance. Ann. Med. 2013; 45: 242–253.
16. Wu W. C., Wang C. Y. Association between non-alcoholic fatty pancreatic disease (NAFPD) and the metabolic syndrome: case-control retrospective study. Cardiovasc Diabetol. 2013; 12: 77–80.
17. Ogilvie R. The island of Langerhans in 19 cases of obesity. J Pathol. 1933. 37 (3): 473–481.
18. Bellentani S., Saccoccio G., Masutti F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Annals of internal medicine. 2000; 132 (2): 112–7.
19. Ivashkin V. T., Drapkina O. M. The prevalence of non-alcoholic fatty liver disease in Russian Federation. UEGW/WCOG GASTRO. 2009; Nov.: 21–25.
20. Rahman R. N., I J. A. Nonalcoholic fatty liver disease without cirrhosis is an emergent and independent risk factor of hepatocellular carcinoma: A population-based study. Hepatology (Baltimore). 2012; 56: 241–243.
21. Rotman Y., Sanyal A. J. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017; 66: 180–190.
22. Guh D., Zhang W., Bansback N., et al. The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009; 9: 88–90.
23. Tan W., Gao M., Liu N., et al. Body Mass Index and Risk of Gallbladder Cancer: Systematic Review and Meta-Analysis of Observational Studies. Nutrients. 2015; 7 (10): 8321–8334.
24. Tsai C-J., Leitzmann M., Willett W., et al. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut. 2006; 55 (5): 708–14.
25. Mathus-Vliegen E., Van Ierland-Van Leeuwen M., Terpstra A. Determinants of gallbladder kinetics in obesity. Dig Dis Sci. 2004; 49 (1): 9–16.
26. Stahlberg D., Rudling M., Angelin B., et al. Hepatic cholesterol metabolism in human obesity. Hepatology. 1997; 25: 1447–1450.
Review
For citations:
Tikhonov S.V., Bakulina N.V., Simanenkov V.I. Overweight and obese patients on gastroenterological visit. Medical alphabet. 2022;(12):7-11. (In Russ.) https://doi.org/10.33667/2078-5631-2022-12-7-11
Views:
336
Email this article 